candesartan has been researched along with Dry Eye in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moss, SE | 1 |
| Klein, R | 1 |
| Sjølie, AK | 1 |
| Chaturvedi, N | 1 |
| Malm, AR | 1 |
| Fuller, JH | 1 |
| Porta, M | 1 |
1 trial available for candesartan and Dry Eye
| Article | Year |
|---|---|
Angiotensin receptor blockade not related to history of dry eye symptoms and treatment in The Diabetic Retinopathy Candesartan Trials (DIRECT).
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitu | 2011 |